Tepnel in antibiotic development collaboration agreement
Tepnel Life Sciences, of Manchester in the UK, has entered into a collaborative agreement with Professor John McCarthy, Professor of Chemical Biology at UMIST (University of Manchester Institute of Science and Technology) to develop novel ribosome-based antimicrobial screening technologies.
Tepnel Life Sciences, of Manchester in the UK, has entered into a collaborative agreement with Professor John McCarthy, Professor of Chemical Biology at UMIST (University of Manchester Institute of Science and Technology) to develop novel ribosome-based antimicrobial screening technologies.
These are intended to enable pharmaceutical and biotechnology companies to identify compounds that have antimicrobial properties, thus accelerating the discovery of new antibiotics.
The new technology will be based on post-transcriptional gene expression, a field in which Professor McCarthy is a leading figure. 'In the course of this collaboration we hope to pursue new strategies that will help us understand how to target key processes in pathogenic organisms,' he said.
All intellectual property resulting from the collaborative screening technology development will belong to Tepnel, and it plans to offer this to customers in the biopharmaceutical sector. According to Ben Matzilevich, ceo of Tepnel Life Sciences, Professor McCarthy brings with him 'a wealth of experience and knowledge in post-transcriptional research, which complements our own expertise with RNA analysis and the development of marketable products and services from these technologies.'